ABEVMY
Google image searchProduct monograph
Active ingredient
bevacizumab, 400 MG/16 ML
DIN: 02522160
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINLGE-USE VIAL
Schedule: Prescription / Schedule D
Company: BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Date: 15-MAY-2023
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FG — VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors (ATC, ATC/DDD)
- L01FG01 — BEVACIZUMAB (ATC/DDD)
Reference brand drug: Avastin
